<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37978232</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1348-4214</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Hypertension research : official journal of the Japanese Society of Hypertension</Title><ISOAbbreviation>Hypertens Res</ISOAbbreviation></Journal><ArticleTitle>Calcium channel blockers may reduce the development of long COVID in females.</ArticleTitle><Pagination><StartPage>934</StartPage><EndPage>943</EndPage><MedlinePgn>934-943</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41440-023-01501-w</ELocationID><Abstract><AbstractText>With the rising numbers of patients infected with severe acute respiratory syndrome coronavirus 2, long coronavirus disease 2019 (COVID-19)-a sequelae of COVID-19-has become a major problem. Different sexes and age groups develop different long COVID symptoms, and the risk factors for long COVID remain unclear. Therefore, we performed subgroup analyses of patients with COVID-19, classifying them into different groups. In this multicenter cohort study, using an original questionnaire, we examined patients (&#x2265;18 years old) diagnosed with COVID-19 from November 2020 to March 2022 and hospitalized at participating medical facilities. In total, 1066 patients were registered (361 female, 620 male). Hypertension was the most common comorbidity (n&#x2009;=&#x2009;344; 32.5%). Females with hypertension were significantly less likely to develop long COVID symptoms than those without hypertension (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.27-0.98; p&#x2009;=&#x2009;0.043). In females, Ca channel blocker administration, rather than having hypertension, was significantly associated with reductions in the frequency of alopecia (OR 0.14, 95% CI 0.03-0.67, p&#x2009;=&#x2009;0.015), memory impairment (OR 0.14, 95% CI 0.02-0.82, p&#x2009;=&#x2009;0.029), sleeping disorders (OR 0.17, 95% CI 0.04-0.67, p&#x2009;=&#x2009;0.012), tinnitus (OR 0.23, 95% CI 0.05-0.98, p&#x2009;=&#x2009;0.047), sputum (OR 0.31, 95% CI 0.10-0.92, p&#x2009;=&#x2009;0.035), and fever (OR 0.33, 95% CI 0.12-0.93, p&#x2009;=&#x2009;0.036). Several long COVID symptoms, including alopecia, were significantly negatively associated with Ca channel-blocker administration in female patients with long COVID. Calcium channel blockers may reduce the development of long COVID in females.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to The Japanese Society of Hypertension.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ozawa</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kimura</LastName><ForeName>Ryusei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terai</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. hidekit926@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan. hidekit926@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takemura</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan. rtakemura@keio.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namkoong</LastName><ForeName>Ho</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Keitaro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yagi</LastName><ForeName>Kazuma</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Keiyu Hospital, Yokohama, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asakura</LastName><ForeName>Takanori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masaki</LastName><ForeName>Katsunori</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chubachi</LastName><ForeName>Shotaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyata</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohgino</LastName><ForeName>Keiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawada</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centers and Institutes, Health Center, Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kagyo</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Keiyu Hospital, Yokohama, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odani</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, National Hospital Organization Hokkaido Medical Center, Hokkaido, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuwahara</LastName><ForeName>Naota</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Allergology and Respiratory Medicine, Showa University Koto Toyosu Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakachi</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yasunori</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukunaga</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hypertens Res</MedlineTA><NlmUniqueID>9307690</NlmUniqueID><ISSNLinking>0916-9636</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Hypertens Res. 2024 Apr;47(4):984-986. doi: 10.1038/s41440-024-01587-w</RefSource><PMID Version="1">38297181</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000505" MajorTopicYN="N">Alopecia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="Y">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihypertensive drug</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>18</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37978232</ArticleId><ArticleId IdType="doi">10.1038/s41440-023-01501-w</ArticleId><ArticleId IdType="pii">10.1038/s41440-023-01501-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bechman K, Yates M, Mann K, Nagra D, Smith LJ, Rutherford AI, et al. Inpatient COVID-19 mortality has reduced over time: results from an observational cohort. PLOS One. 2022;17:e0261142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261142</ArticleId><ArticleId IdType="pubmed">35025917</ArticleId><ArticleId IdType="pmc">8757902</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F, Perego E. How and why patients made long COVID. Soc Sci Med. 2021;268:113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId><ArticleId IdType="pmc">7539940</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId><ArticleId IdType="pmc">8440190</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat Commun. 2022;13:1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId><ArticleId IdType="pubmed">35413949</ArticleId><ArticleId IdType="pmc">9005552</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId><ArticleId IdType="pmc">7611399</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4:e2128568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId><ArticleId IdType="pmc">8515212</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4:e2111417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId><ArticleId IdType="pmc">8155823</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#x142;ywaczewska-Jakubowska M, Chudzik M, Babicki M, Kapusta J, Jankowski P. Lifestyle, course of COVID-19, and risk of Long-COVID in non-hospitalized patients. Front Med. 2022;9:1036556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1036556</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazukhina E, Andreeva M, Spiridonova E, Bobkova P, Shikhaleva A, El-Taravi Y, et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med. 2022;20:244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02448-4</ArticleId><ArticleId IdType="pubmed">35794549</ArticleId><ArticleId IdType="pmc">9257572</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Torres-Macho J, Velasco-Arribas M, Plaza-Canteli S, Arias-Naval&#xf3;n JA, Hern&#xe1;ndez-Barrera V, et al. Preexisting hypertension is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: a case-control study. J Hum Hypertens. 2022;36:582&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41371-022-00660-6</ArticleId><ArticleId IdType="pubmed">35173268</ArticleId><ArticleId IdType="pmc">8853057</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Saddik B, Ramakrishnan RK, AlSwaidan N, AlAnazi A, Alhazmi D, et al. Long term predictors of breathlessness, exercise intolerance, chronic fatigue and well-being in hospitalized patients with COVID-19: a cohort study with 4 months median follow-up. J Infect Public Health. 2022;15:21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2021.11.016</ArticleId><ArticleId IdType="pubmed">34861604</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Saddik B, AlSwaidan N, AlAnazi A, Ramakrishnan RK, Alhazmi D, et al. Prevalence and predictors of post-acute COVID-19 Syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow-up. PLOS One. 2021;16:e0260568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260568</ArticleId><ArticleId IdType="pubmed">34874962</ArticleId><ArticleId IdType="pmc">8651136</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId><ArticleId IdType="pmc">9388369</ArticleId></ArticleIdList></Reference><Reference><Citation>Terai H, Ishii M, Takemura R, Namkoong H, Shimamoto K, Masaki K, et al. Comprehensive analysis of long COVID in a Japanese nationwide prospective cohort study. Respir Investig. 2023;30:802-814.</Citation></Reference><Reference><Citation>Ishii M, Terai H, Kabata H, Masaki K, Chubachi S, Tateno H, et al. Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: a multicenter retrospective study. J Infect. 2020;81:e3&#x2013;e5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.052</ArticleId><ArticleId IdType="pubmed">32920063</ArticleId><ArticleId IdType="pmc">7482596</ArticleId></ArticleIdList></Reference><Reference><Citation>Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21:855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06536-3</ArticleId><ArticleId IdType="pubmed">34418980</ArticleId><ArticleId IdType="pmc">8380115</ArticleId></ArticleIdList></Reference><Reference><Citation>Adjei S, Hong K, Molinari NM, Bull-Otterson L, Ajani UA, Gundlapalli AV, et al. Mortality risk among patients hospitalized primarily for COVID-19 during the omicron and delta variant pandemic periods - United States, April 2020&#x2013;June 2022. Morb Mortal Wkly Rep. 2022;71:1182&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7137a4</ArticleId></ArticleIdList></Reference><Reference><Citation>Otake S, Chubachi S, Namkoong H, Nakagawara K, Tanaka H, Lee H, et al. Clinical clustering with prognostic implications in Japanese COVID-19 patients: report from Japan COVID-19 Task Force, a nation-wide consortium to investigate COVID-19 host genetics. BMC Infect Dis. 2022;22:735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07701-y</ArticleId><ArticleId IdType="pubmed">36104674</ArticleId><ArticleId IdType="pmc">9472186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang LK, Sun Y, Zeng H, Wang Q, Jiang X, Shang WJ, et al. Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov. 2020;6:96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-00235-0</ArticleId><ArticleId IdType="pubmed">33349633</ArticleId><ArticleId IdType="pmc">7752915</ArticleId></ArticleIdList></Reference><Reference><Citation>Solaimanzadeh I. Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19. Cureus. 2020;12:e8069.</Citation><ArticleIdList><ArticleId IdType="pubmed">32411566</ArticleId><ArticleId IdType="pmc">7219014</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Zhu Y, Hong Y. Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis. Hypertension. 2020;76:e13&#x2013;e14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15572</ArticleId><ArticleId IdType="pubmed">32458694</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawara K, Namkoong H, Terai H, Masaki K, Tanosaki T, Shimamoto K, et al. Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol. BMJ Open Respir Res. 2021;8:e001015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjresp-2021-001015</ArticleId><ArticleId IdType="pubmed">34836924</ArticleId><ArticleId IdType="pmc">8628335</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html .</Citation></Reference><Reference><Citation>Bucciarelli V, Nasi M, Bianco F, Seferovic J, Ivkovic V, Gallina S, et al. Depression pandemic and cardiovascular risk in the COVID-19 era and long COVID syndrome: gender makes a difference. Trends Cardiovasc Med. 2022;32:12&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2021.09.009</ArticleId><ArticleId IdType="pubmed">34619336</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Mart&#xed;n-Guerrero JD, Pellicer-Valero &#xd3;J, Navarro-Pardo E, G&#xf3;mez-Mayordomo V, Cuadrado ML, et al. Female sex is a risk factor associated with long-term post-COVID related-symptoms but not with COVID-19 symptoms: the LONG-COVID-EXP-CM multicenter study. J Clin Med. 2022;11:413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11020413</ArticleId><ArticleId IdType="pubmed">35054108</ArticleId><ArticleId IdType="pmc">8778106</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Chubachi S, Namkoong H, Asakura T, Tanaka H, Otake S, et al. Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force. BMC Infect Dis. 2022;22:935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07927-w</ArticleId><ArticleId IdType="pubmed">36510172</ArticleId><ArticleId IdType="pmc">9744033</ArticleId></ArticleIdList></Reference><Reference><Citation>Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8:e46&#x2013;e47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30216-2</ArticleId><ArticleId IdType="pubmed">32353251</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain MA, Hossain KMA, Saunders K, Uddin Z, Walton LM, Raigangar V, et al. Prevalence of Long COVID symptoms in Bangladesh: a prospective inception cohort study of COVID-19 survivors. BMJ Glob Health. 2021;6:e006838.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-006838</ArticleId><ArticleId IdType="pubmed">34906986</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId><ArticleId IdType="pmc">9212672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Covid-19: long covid risk is lower with omicron than delta, researchers find. BMJ. 2022;377:o1500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1500</ArticleId><ArticleId IdType="pubmed">35714995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard JP, Nicholson BD, Lee J, McGagh D, Sherlock J, Koshiaris C, et al. Association between blood pressure control and coronavirus disease 2019 outcomes in 45 418 symptomatic patients with hypertension: an observational cohort study. Hypertension. 2021;77:846&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.16472</ArticleId><ArticleId IdType="pubmed">33325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30116-8</ArticleId><ArticleId IdType="pubmed">32171062</ArticleId><ArticleId IdType="pmc">7118626</ArticleId></ArticleIdList></Reference><Reference><Citation>Nozari F, Hamidizadeh N. The effects of different classes of antihypertensive drugs on patients with COVID-19 and hypertension: a mini-review. Int J Hypertens. 2022;2022:5937802.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/5937802</ArticleId><ArticleId IdType="pubmed">35075396</ArticleId><ArticleId IdType="pmc">8783136</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId><ArticleId IdType="pmc">8893149</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohyama M, Matsudo K, Fujita T. Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: insight into the pathophysiology with implication for better management. J Dermatol. 2022;49:939&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.16475</ArticleId><ArticleId IdType="pubmed">35633047</ArticleId><ArticleId IdType="pmc">9348110</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfi S, Alijanpour R, Aryanian Z, Ezoji K, Mahmoudi M. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. J Med Life. 2022;15:631&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="doi">10.25122/jml-2021-0380</ArticleId><ArticleId IdType="pubmed">35815081</ArticleId><ArticleId IdType="pmc">9262270</ArticleId></ArticleIdList></Reference><Reference><Citation>Iseki K. Chronic kidney disease in Japan. Intern Med. 2008;47:681&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.47.0906</ArticleId><ArticleId IdType="pubmed">18421182</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990&#x2013;2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30045-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kisu.2021.11.003</ArticleId><ArticleId IdType="pubmed">35529086</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, de Oliveira MHS, Peligro PJ, Velasco JV, Macaranas I, Ver AT, et al. Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: A systematic review and meta-analysis. J Clin Med. 2022;11:7314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId><ArticleId IdType="pmc">9787827</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition . Accessed 14 Sep 2023.</Citation></Reference><Reference><Citation>Kow CS, Ramachandram DS, Hasan SS. Use of calcium channel blockers and the risk of all-cause mortality and severe illness in patients with COVID-19: a systematic review and meta-analysis. J Cardiovasc Pharm. 2022;79:199&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000001144</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>